The present invention relates to a novel process for preparing a novel form of the (-)-enantiomer of 5-methoxy-2-ÄÄ(4-methoxy-35-dimethyl-2-pyridinyl)-methylÜsulfinylÜ-1H -benzimidazole i.e. S-omeprazole. More specifically it relates to a process for preparing trihydrate of magnesium salt of S-omeprazole. Furthermore the present invention also relates to new intermediates used in that process.

The present invention relates to a novel form of the (-)-enantiomer of 5-methoxy-2-[[(4-methoxy-35-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole i.e. S-omeprazole. More specifically it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore the present invention also relates to new ...

The present invention relates to an improved method for the synthesis of the (S)- or (R)- enantiomer of omeprazole characterized in that 2-[[(4-X-35-dimethylpyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole or 2-[[(4-X-35-dimethyl-1-oxidopyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole wherein X is a leaving group is oxidized into the corresponding sulphoxide which is obtained as a crystalline compound. Recrystallisation of the thus obtained sulphoxide results in a compound of enhanced ch...

The present invention relates to an improved method for the synthesis of the (S)- or (R)- enantiomer of omeprazole characterized in that 2-[[(4-X-35-dimethylpyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole or 2-[[(4-X-35-dimethyl-1-oxidopyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole wherein X is a leaving group is oxidized into the corresponding sulphoxide which is obtained as a crystalline compound. Recrystallisation of the thus obtained sulphoxide results in a compound of enhanced ch...

The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-35-dimethyl-2 -pyridinyl)-methyl]sulfinyl]-1H-benzimidazole i.e. S-omeprazole. More specifically it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore the present invention also relates ...

A process for the manufacture of omeprazole or esomeprazole from pyrmethyl alcohol via pyrmethyl chloride and pyrmetazole characterized in that the whole reaction sequence is carried out without any isolation or purification of intermediates. Further the reaction is carried out in a solvent system common for the whole reaction sequence and inert to the reactants formed during the process and used in the process and comprises a water immiscible organic solvent and a specified amount of water.